Menopausal Flushing

Novel Oral Tx Dramatically Reduces Menopausal Flushing

Treatment part of new class of neurokinin 3 receptor antagonists

• SAVESAVED

• by Kristen Monaco, Staff Writer, MedPage TodayMarch 14, 2018

A neurokinin 3 receptor (NK3R) antagonist was effective at improving vasomotor symptoms without the need for estrogen exposure, both in the short and long-term, researchers reported.

The oral NK3R antagonist MLE4901 was able to reduce the frequency of hot flashes by 72% by day 3 of treatment versus baseline symptoms (95% CI -81.3% to -63.5%) and a 51% improvement in frequency with the oral treatment compared with those on placebo, according to Julia K. Prague, MBBS, of Imperial College London, and colleagues./.../